Cytokinetics (CYTK) EVP sells 3,500 shares after option exercise

Rhea-AI Filing Summary

Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised options and sold shares of company stock. He exercised non-qualified stock options for 3,500 shares of Common Stock at $7.80 per share, then completed an open-market sale of 3,500 Common Stock shares at $65.69 per share on the same date. Following these transactions, he directly holds 153,902 shares of Common Stock.

Insights

Equity compensation analyst

EVP exercised 3,500 options and sold the same number of shares, a small, mixed transaction.

Executive Vice President of Research & Development Fady Ibraham Malik exercised non-qualified stock options for 3,500 shares at $7.80 per share and sold 3,500 Common Stock shares at $65.69 per share. This is a classic exercise-and-sell pattern.

After these movements, he directly holds 153,902 Common Stock shares, indicating the sale represents a small portion of his overall holdings. The derivativeSummary shows no remaining position from this specific option lot, suggesting that option grant was fully exercised in this event.

Overall, this looks like a routine liquidity transaction linked to compensation rather than a large directional bet, given the modest size relative to his remaining stake and the one-for-one match between exercised and sold shares.

Insider Trade Summary 10b5-1

Net Seller: 3,500 shares ($229,915)

Net Sell 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 3,500 shs ($230K)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	3,500	$0.00	--
Exercise	Common Stock	3,500	$7.80	$27K
Sale	Common Stock	3,500	$65.69	$230K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 54,886 shares (Direct, null); Common Stock — 157,402 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 3,500 shares Sale price: $65.69 per share Options exercised: 3,500 shares +3 more

6 metrics

Shares sold 3,500 shares Common Stock open-market sale

Sale price $65.69 per share Price for 3,500 Common Stock shares sold

Options exercised 3,500 shares Non-qualified stock option exercise into Common Stock

Exercise price $7.80 per share Exercise price of Non-Qualified Stock Option

Shares held after sale 153,902 shares Direct Common Stock ownership after transactions

Option expiration February 27, 2028 Original expiration date of exercised stock option

Key Terms

open-market sale, Non-Qualified Stock Option (Right to Buy), derivative security, derivative exercise/conversion

4 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/21/2026		M		3,500	A	$7.8	157,402	D
Common Stock	04/21/2026		S		3,500	D	$65.69	153,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$7.8	04/21/2026		M			3,500	03/27/2018	02/27/2028	Common Stock	3,500	$0	54,886	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cytokinetics (CYTK) EVP Fady Malik report?

He reported exercising non-qualified stock options for 3,500 shares and selling 3,500 shares of Cytokinetics Common Stock. Both transactions occurred on the same date and involved direct ownership. Afterward, he continued to hold a significant direct position in company shares.

How many Cytokinetics (CYTK) shares did the EVP sell and at what price?

He sold 3,500 shares of Cytokinetics Common Stock in an open-market transaction at a price of $65.69 per share. This sale followed an option exercise for the same number of shares and modestly reduced his direct shareholdings.

At what price did Cytokinetics (CYTK) EVP exercise his stock options?

He exercised non-qualified stock options covering 3,500 shares of Cytokinetics Common Stock at an exercise price of $7.80 per share. These options related to a grant exercisable into Common Stock and were paired with an equal-sized share sale.

How many Cytokinetics (CYTK) shares does the EVP hold after the Form 4 transactions?

Following the reported transactions, he directly holds 153,902 shares of Cytokinetics Common Stock. This figure reflects his position after exercising 3,500 options and selling 3,500 shares, indicating that the activity affected only a small portion of his overall stake.

What type of derivative security did Cytokinetics (CYTK) EVP exercise?

He exercised a Non-Qualified Stock Option (Right to Buy) covering 3,500 underlying shares of Cytokinetics Common Stock at a $7.80 exercise price. This derivative position had an original expiration date in 2028 before being fully exercised in the reported transaction.